Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Indonesia to ink Pfizer, AstraZeneca vaccine deals as awaits Sinovac clearance

Tue, 29th Dec 2020 11:38

(Recasts, adds vox pops on vaccine hesitancy)

By Stanley Widianto and Yuddy Cahya Budiman

JAKARTA, Dec 29 (Reuters) - Indonesia is poised to secure
coronavirus vaccines from Pfizer and AstraZeneca, the health
minister said on Tuesday, as it awaits authorisation to begin
its inoculation programme with a third drug, by China's Sinovac.

Budi Gunadi Sadikin said a 50-million-dose deal with
AstraZeneca would be finalised before the end of the
year, and one of the same size with Pfizer in the first
week of January.

The first shots for both those drugs, which have gained
regulatory approval in many western countries, are not scheduled
to arrive for months, the minister told his first news
conference.

So Indonesia plans to start vaccinations with the Sinovac
treatment, of which it secured 1.2 million doses this
month and expects 1.8 million more in January, once it gains
emergency use clearance.

Interim results from its phase III trial are expected to be
delivered to Indonesia's Food and Drug Agency next month.

Budi said the country's 1.3 million front-line health
workers would get priority in the first wave of vaccinations
between January and April. "They are the most important group of
people in our battle against the pandemic," he told a news
conference.

The world's fourth most populous country has had over
727,000 confirmed COVID cases and 21,700 deaths, among Asia's
highest tallies.

Public servants will be next in line for shots, with those
in infection "red-zones" aged between 18 and 59 prioritised in a
second round of vaccinations.

Indonesia is focusing its programme on that age range rather
than the elderly in an effort to safeguard the working
population.

Bambang Heriyanto, corporate secretary of state-owned
drugmaker Bio Farma, said that strategy would allow Indonesia to
reach herd immunity.

Including Tuesday's announcement, Indonesia has secured 329
million vaccine doses, including about 125 million from Sinovac,
50 million from Novavax and 54 million from global vaccine
programme COVAX.

The AstraZeneca vaccines are expected to arrive in the
second quarter of 2021 and Pfizer's in the third quarter,
according to a slide presentation by Budi.

The companies were not immediately available for comment.

IS IT SAFE? IS IT HALAL?

The vaccine deals met with mixed reactions on the streets of
the capital Jakarta on Tuesday.

"There's lots of diseases with no cure, but there's already
(a) cure for COVID," said 25-year-old radio announcer Cindy
Lauw, "I'm just wary."

Suhaimi, a 55-year-old retiree, said he would await trial
results, and news about whether the vaccine was permitted under
Islam.

A December survey by Indonesian pollster Saiful Mujani
Research and Consulting showed 37% of 1,202 respondents were
willing to be vaccinated, while 40% would consider it and 17%
would refuse.

While acknowledging the essential role of vaccinations,
epidemiologist Pandu Riono warned against over-reliance on them.

"Vaccines are the second step in prevention, the first is
behaviour and surveillance, testing, contact tracing and
isolation," he said.
(Additional reporting by Angie Teo;
Writing by Kate Lamb;
Editing by Martin Petty, Robert Birsel and John Stonestreet)

More News
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.